Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours By Ogkologos - July 21, 2025 296 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer EMA Recommends Extension of Indications for Selpercatinib MOST POPULAR Health inequalities: “We have a moral duty to reduce them” February 15, 2022 Drug Regimen Boosts Survival of People with Advanced Colorectal Cancer May 24, 2023 Couple Married For 48 Years Shared A Touching Moment As They... August 22, 2019 Activity and Safety of Regorafenib Plus Nivolumab in First-Line Treatment for... February 22, 2024 Load more HOT NEWS A celebration of peer review Sacituzumab Govitecan Demonstrates Significant Improvement in PFS in Heavily Pretreated, Locally... Adjuvant mRNA-4157 Plus Pembrolizumab Prolongs RFS versus Pembrolizumab Alone in Patients... It Might Sound Trite But…
